Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,137
Regeneron Pharma Is Maintained at Buy by Truist Securities
Regeneron Pharmaceuticals Analyst Ratings
Express News | Regeneron Pharmaceuticals Inc : Truist Securities Cuts Target Price to $1137 From $1200
Jasper Gains 11% on Data for Briquilimab in Urticaria
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.